opioid withdrawal symptoms. Mental and behavioural disorders due to use of opioids
Conditions
Interventions
Intervention 1: Intervention group: receive topiramate ( 100 mg/day), 2 weeks. Intervention 2: Control group: receive placebo for 2 weeks.
Treatment - Drugs
Placebo
Intervention group: receive topiramate ( 100 mg/day), 2 weeks.
Control group: receive placebo for 2 weeks.
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
19 Years to 59 Years
Inclusion criteria
Inclusion criteria: Individuals are included if they fulfil DSM-IV-TR criteria for opioid- like substance dependency. However, Patients are not included if they have opioid- like withdrawal syndrome during the recruitment period. Exclusion criteria: concomitant use of alcohol, stimulants as well as benzodiazepines; having severe medical comorbidities; patients who start to take any psychiatric medication or any significant change in dose of medication during the study and follow-up period.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of subjective withdrawal symptoms. Timepoint: At the days: 1, 3, 5, 7 and 14. Method of measurement: (OWSC) opiate withdrawal symptoms checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Amir Rezaei Aardani
Mashhad University of Medical Sciences
Outcome results
None listed